Literature DB >> 21900098

Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma.

Emil Lou1, Scott Turner, Ashley Sumrall, David A Reardon, Annick Desjardins, Katherine B Peters, John H Sampson, Henry S Friedman, James J Vredenburgh.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21900098     DOI： 10.1200/JCO.2011.36.1865

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  11 in total

Review 1.  Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors.

Authors:  Terri S Armstrong; Patrick Y Wen; Mark R Gilbert; David Schiff
Journal:  Neuro Oncol       Date:  2012-02-03       Impact factor: 12.300

2.  Atypical reversible posterior leukoencephalopathy syndrome (RPLS) induced by cediranib in a patient with metastatic rectal cancer.

Authors:  Christina A K Kim; Julie Price-Hiller; Quincy S Chu; Keith Tankel; Ron Hennig; Michael B Sawyer; Jennifer L Spratlin
Journal:  Invest New Drugs       Date:  2014-05-23       Impact factor: 3.850

3.  Primary brain tumors and posterior reversible encephalopathy syndrome.

Authors:  Carlos Kamiya-Matsuoka; David Cachia; Adriana Olar; Terri S Armstrong; Mark R Gilbert
Journal:  Neurooncol Pract       Date:  2014-09-14

4.  Posterior Reversible Encephalopathy Syndrome in Patients With Cancer.

Authors:  Samuel Singer; Christian Grommes; Anne S Reiner; Marc K Rosenblum; Lisa M DeAngelis
Journal:  Oncologist       Date:  2015-06-01

Review 5.  Posterior reversible encephalopathy syndrome induced by anti-VEGF agents.

Authors:  Camille Tlemsani; Olivier Mir; Pascaline Boudou-Rouquette; Olivier Huillard; Karin Maley; Stanislas Ropert; Romain Coriat; François Goldwasser
Journal:  Target Oncol       Date:  2011-11-17       Impact factor: 4.493

Review 6.  Delirium in patients with cancer: assessment, impact, mechanisms and management.

Authors:  Peter G Lawlor; Shirley H Bush
Journal:  Nat Rev Clin Oncol       Date:  2014-09-02       Impact factor: 66.675

Review 7.  Posterior reversible encephalopathy syndrome (PRES) induced by pazopanib, a multi-targeting tyrosine kinase inhibitor, in a patient with soft-tissue sarcoma: case report and review of the literature.

Authors:  Shoichi Deguchi; Koichi Mitsuya; Yoko Nakasu; Nakamasa Hayashi; Hirohisa Katagiri; Hideki Murata; Junji Wasa; Mitsuru Takahashi; Masahiro Endo
Journal:  Invest New Drugs       Date:  2017-10-25       Impact factor: 3.850

8.  Posterior reversible encephalopathy syndrome associated with the use of chemotherapeutic agents: a rare complication after treatment with vinorelbine.

Authors:  Ines Gil; Filipa Serrazina; Miguel Pinto; Miguel Viana-Baptista
Journal:  BMJ Case Rep       Date:  2020-02-16

9.  Cisplatin-induced posterior reversible encephalopathy syndrome and successful re-treatment in a patient with non-seminomatous germ cell tumor: a case report.

Authors:  Muhammad Nauman Zahir; Nehal Masood; Munira Shabbir-Moosajee
Journal:  J Med Case Rep       Date:  2012-11-29

10.  Reversible posterior leukoencephalopathy syndrome induced by pazopanib.

Authors:  Leonidas Chelis; Vasilios Souftas; Kiriakos Amarantidis; Nikolaos Xenidis; Eleni Chamalidou; Prokopios Dimopoulos; Prodromos Michailidis; Evagelos Christakidis; Panagiotis Prassopoulos; Stylianos Kakolyris
Journal:  BMC Cancer       Date:  2012-10-22       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.